Are Patients with Inflammatory Bowel Disease Receiving Optimal Care?

University of Hartford, West Hartford, Connecticut, United States
The American Journal of Gastroenterology (Impact Factor: 10.76). 07/2005; 100(6):1357-61. DOI: 10.1111/j.1572-0241.2005.40849.x
Source: PubMed


Guidelines have been published as a framework for therapy of patients with inflammatory bowel disease (IBD). The purpose of this study was to determine whether patients referred for a second opinion were receiving therapy in accordance with practice guidelines.
Patients with luminal IBD under the care of a gastroenterologist who sought a a second opinion at Brigham and Women's Hospital between January 2001 and April 2003 were enrolled in this study. Clinical information was obtained by direct patient interview at the time of initial patient visit and by a review of prior records. Data obtained included the diagnosis, clinical symptoms, prior medical therapy, preventive measures for metabolic bone disease, and colon-cancer screening.
The study population consisted of 67 consecutive patients: 21 with ulcerative colitis, 44 with Crohn's disease and 2 in whom the diagnosis of IBD could not be confirmed. Of the 65 patients with confirmed IBD, 56 patients had symptoms of active disease and 9 were asymptomatic. All analyses were carried out on the 56 patients with active disease. Of the 33 patients treated with aminosalicylates, 21 (64%) were not receiving maximal doses. Nine of 12 (75%) patients with distal ulcerative colitis were not receiving rectal aminosalicylate therapy. Within 6 months of their clinic visit, 35 patients had received corticosteroid therapy, and 27 (77%) patients had been treated with corticosteroids for greater than 3 months. In 16 of 27 (59%) there was no attempt to start steroid sparing medications such as 6-mercaptopurine (6MP), azathioprine, or infliximab. Of the 11 patients treated with either 6MP or azathioprine, 9 (82%) were suboptimally dosed without an attempt to increase dosage. Of the 27 patients on prolonged corticosteroid therapy 21 (78%) received inadequate treatment to prevent metabolic bone disease. Three of 9 patients (33%) meeting indications for surveillance colonoscopy for dysplasia had not undergone colonoscopy at the appropriate interval.
Patients with IBD often do not receive optimal medical therapy. In particular, there is suboptimal dosing of 5-ASA and immunomodulatory medications, prolonged use of corticosteroids, failure to use steroid-sparing agents, inadequate measures to prevent metabolic bone disease, and inadequate screening for colorectal cancer.

Full-text preview

Available from:
  • Source
    • "The quality of treatment has been increasingly recognized as an important aspect. It is particularly important in diseases such as UC and CD [8]. However, there is only limited information about it. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Crohn's disease (CD) and ulcerative colitis (UC) are the most frequent inflammatory bowel disorders (IBD). IBD cause a significant burden to society due to extensive health care utilization from the first clinical symptoms until diagnosis and thereafter due to direct and indirect costs. Besides the socio-economic impact of CD and UC, gastrointestinal and extraintestinal symptoms affect quality of life, but there is remarkably little data about the quality of treatment as assessed by patient satisfaction, quality of life and adherence to guidelines. Thus the aim of this study was to identify variables that influence quality of treatment and quality of life as well as patient satisfaction. The Essener Zirkel Study was a cross sectional study of 86 IBD-patients with a confirmed diagnosis of CD or UC. They were recruited at primary, secondary and tertiary care settings. Quality of treatment, quality of life and patient satisfaction were evaluated. Consulting behaviour and number of examinations, duration of disease and variables regarding adherence to guidelines were evaluated, too. 59 (69%) patients had CD and 27 had UC (31%). 19% spent more than four years until the suspected diagnosis of IBD was confirmed and visited more than five physicians. All patients showed a significantly reduced quality of life compared to the 1998 German normative population. In spite of being under medical treatment, nearly half of the patients suffered from strong quality of life restricting symptoms. Over all, 35% described their treatment as moderate or bad. Patients who consulted psychotherapists and non-medical practitioners suffered significantly less from depression. Besides structural deficiencies due to the health care policy, we revealed the adherence to guidelines to be a problem area. Our findings support the assumption, that providing better health care and especially maintaining constant patient-physician communication improves patient satisfaction.
    Full-text · Article · Feb 2009 · BMC Health Services Research
  • Source
    • "Since surgery will generally only be performed for severe disease not responding to medical therapy, the proportion of patients potentially treated with biologic therapy in the future is likely to be much higher. Even so, there is evidence of under-treatment with biologic agents, especially in Europe (Reddy et al 2005). Alternative treatments are also needed for those who develop immunogenicity on infl iximab (estimated at 50% or more, depending on dosing schedule, concomitant therapy, and assay technique) (Vermiere et al 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Since inflammatory bowel disease (IBD) represents a state of dysregulated inflammation, drugs that augment the anti-inflammatory response have the potential to downregulate inflammation and thereby hopefully modify the disease. Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has proinflammatory effects in the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown in Phase III trials to achieve and maintain clinical response and remission in Crohn's disease patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to severely active Crohn's disease, but it is not yet licensed in Europe or the US. It is not possible to construct an algorithm for treatment, but when compared with infliximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of administration. These two factors may be sufficient to promote it up the pecking order of anti-TNF agents.
    Full-text · Article · Feb 2007 · International Journal of Nanomedicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung 5-Aminosalicylate (5-ASA) und Steroide gelten als Medikamente der Basistherapie bei Patienten mit chronisch entzndlichen Darmerkrankungen (CED). Whrend der Stellenwert von 5-ASA in der Therapie des Morbus Crohn (MC) zunehmend diskutiert wird, stellt die Colitis ulcerosa (CU) unverndert ihre Hauptindi- kation dar. In dieser Indikation spielen sie sowohl in der Akut- therapie eines milden bis moderaten Schubes als auch in der Remissionserhaltung eine wichtige Rolle. Zudem ist die Wirk- samkeit von topisch applizierten 5-ASA-Prparaten in der Lo- kaltherapie von milden bis moderaten Schben einer Proctitis ulcerosa bzw. linksseitigen Kolitis etabliert und ein additiver Ef- fekt zur oralen Therapie belegt. Der Nutzen von 5-ASA-Prpara- ten in der Chemoprevention CED-assoziierter kolorektaler Karzi- nome wird aus retrospektiven Studien vermutet. Steroide stellen die Therapie der ersten Wahl in der Behandlung des moderat bis stark aktiven Schubes sowohl bei MC als auch bei CU dar. Neben wirkungsarmen, topisch wirksamen Steroiden wie Budesonid soll bei mildem bis moderatem Schub eines primr ileozkalen MC mit oder ohne Befall des rechten Kolons der Vorzug gegeben werden, noch vor 5-ASA-Prparaten oder systemisch wirksamen Steroiden. Die Notwendigkeit einer systemischen Steroidthera- pie muss als prognostisch ungnstiger Indikator einer CED gese- hen werden und soll an den frhzeitigen therapeutischen Einsatz von Immunsuppressiva denken lassen. Eine Dauertherapie mit Abstract 5-aminosalicylates (5-ASA) and steroids constitute a cornerstone of medical therapy in patients with inflammatory bowel diseases (IBD). Whereas the efficacy of 5-ASA in Crohn's disease (CD) is equivocal, ulcerative colitis (UC) is the main indication for this drug. In UC, 5-ASA is effective in the treatment of mild to moder- ate acute disease and in maintenance of remission. Furthermore, 5-ASA topical therapy is an important treatment option in pa- tients with mild to moderate proctitis and/or left-sided UC and shows additive efficacy to oral therapy. From retrospective data a chemo-preventative activity of long-term 5-ASA therapy in UC is delineated. Steroids are treatment of first choice for moderate to severe cases of CD and UC. Budesonide, a modified steroid with less side effects, plays a major role in the treatment of ileo- colonic CD € involvement of the right colon and is used as treat- ment of choice in mild-to-moderate cases. In case of acute, se- vere disease conventional steroids are superior compared to budesonide and therefore budesonide should only be used after considerable improvement of disease activity. The necessity to apply steroids in a given patient represents a negative prognostic indicator for the course of disease and should incite the early in- troduction of immunosuppressive therapy in this case. Steroids are only effective as short term therapy of IBD and are to be avoided for maintenance treatment. In all cases of steroid ther- apy an osteoporosis prophylaxis with calcium and vitamin D is
    No preview · Article ·
Show more